title: Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
abstract: The mechanisms by which esophageal tumors escape immunologic recognition and clearance are only partly understood at the molecular level. Esophageal cancers have been shown to evade host recognition by down-regulation of antigen presentation and production of immunosuppressive factors. Recently, two independent reports have shown that esophageal tumor cells abundantly express Fas ligand (FasL) in vivo. As the triggering agonist for Fas receptor (Fas or APO-1/CD95)-mediated apoptosis of lymphocytes, FasL normally plays immune down-regulatory roles, including activation-induced cell death of T and B cells, as well as maintaining immune privilege in certain organs. Fas ligand expressed by esophageal cell lines has been shown to induce apoptosis of cocultured Fas-sensitive lymphoid cells in vitro. FasL expression by esophageal carcinomas in vivo has been associated with significantly reduced tumor-infiltrating lymphocytes (TILs) in FasL-positive tumor nests, concomitant with significantly increased TIL apoptosis in these nests. These studies support a 'Fas counterattack' mechanism of immune escape in esophageal cancer. By expressing functional Fas ligand, esophageal cancer cells can deplete antitumor lymphocytes by inducing apoptosis. To express functional FasL, esophageal carcinomas also acquire molecular mechanisms to resist autocrine Fas-mediated apoptosis of tumor cells.
authors.affiliation: Department of Medicine, National University of Ireland, Cork, Ireland. J.OConnell@ucc.ie
authors.forename: J
authors.initials: J
authors.lastname: O'Connell
authors.forename: M W
authors.initials: MW
authors.lastname: Bennett
authors.forename: G C
authors.initials: GC
authors.lastname: O'Sullivan
authors.forename: J K
authors.initials: JK
authors.lastname: Collins
authors.forename: F
authors.initials: F
authors.lastname: Shanahan
mesh_terms: D017209:Apoptosis; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000473:pathology; D053222:Fas Ligand Protein; D006801:Humans; D016131:Lymphocyte Subsets / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008562:Membrane Glycoproteins / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology*; D019014:fas Receptor / Q000276:immunology*
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D018124:Receptors, Tumor Necrosis Factor; D019014:fas Receptor